Novel approach to cancer drug given major boost

All cells in the body contain protein kinase B (PKB), a naturally-occurring enzyme that if active prevents cells from committing suicide. Programmed cell death, or apoptosis, is an important process in the body's development, but when this process goes wrong, unregulated cell growth occurs, leading to the development of tumour cells.

Recent research has shown that certain types of genetic damage, common to many cancer cells, lead to the movement of PKB from the interior of the cell to its surface membrane. When PKB attaches to the surface membrane, it becomes active, triggering a signal that tells the cell not to commit suicide. Professor Jeremy Tavaré at ProXara Biotechnology Ltd, a spin-out company at the University of Bristol, believes that by preventing PKB binding to the cell's surface membrane, he can ensure that apoptosis occurs, thus killing the cancer cells.

"There has been a lot of interest in targeting PKB as a way of preventing tumour growth," says Professor Tavaré. "Most of the interest so far has been in developing drugs that block the enzyme's signal. However, such drugs are very non-specific and can have many adverse side effects. We are working on a novel approach to prevent PKB actually binding to the cell membrane."

Professor Tavaré and his team have discovered a drug-like compound, which prevents PKB binding to the cell membrane and makes the tumour cells commit suicide. They now wish to develop this compound to a point at which it could be used in clinical trials.

"Professor Tavaré's research offers a novel approach to cancer drug research," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust, which is funding the research under its Seeding Drug Discover initiative. "Cancer affects very large numbers of people which is why it receives so much attention from those engaged in medical research. But it is a complex disease to tackle and as a result many of the current anti-cancer drugs have unpleasant side -effects. This work has the potential to provide a more targeted approach to drug therapy with fewer adverse effects."

Professor Tavaré says that the drug would be used initially to target lung cancer, the most common cancer in the UK. Almost 38,000 people are diagnosed with this particular cancer each year. If the approach works it could be adapted to treat other types of cancer or even inflammatory diseases such as arthritis or asthma.

"We anticipate that a drug based on this approach may benefit a significant proportion of people with lung cancer," explains Professor Tavaré. "As well as developing the drug itself, we are also working on a way of identifying which individuals are most likely to respond to the drug."

This targeted therapy is based on five years of research by Professor Tavaré and Dr Paul England. The research has now been given a major boost by way of a £2.8 million award to the University of Bristol under the Wellcome Trust's Seeding Drug Discovery initiative. The initiative aims to bridge the funding gap in early-stage drug discovery, assisting researchers to take forward projects in small molecule therapeutics that will be the springboard for further R&D by the biotech and pharmaceutical industry.

Source: Wellcome Trust

Iressa proves just as effective as chemotherapy for lung cancer
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.
A simple blood test for colon cancer
People are often reluctant to undergo a routine but painful colonoscopy -- but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men and women and kills about 50,000 Americans every year.
Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
Study identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
New platinum-phosphate compounds kill ovarian cancer cells
A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.
Two new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
Widely used cancer drug associated with significantly increased risk of blood clots
An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA.
Nontoxic nanoparticle can deliver and track drugs
A nontoxic nanoparticle developed by Penn State researchers is proving to be an all-around effective delivery system for both therapeutic drugs and the fluorescent dyes that can track their delivery.

Novel approach to cancer drug given major boost

Related stories:

News discussion: